The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
|Videos|May 23, 2011
Juanita Madison on Handling the Provenge Process
Author(s)Juanita Madison, MN, RN
Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process
Advertisement
Lead researcher Juanita Madison, MN, RN, AOCN from the Seattle Cancer Care Alliance (SCCA) of a multidisciplinary study looking at Provenge discusses handling the treatment process. Using the Plan-Do-Study-Act quality-improvement model the multidisciplinary task-force devised, implemented, and revised a Provenge treatment strategy.
Advertisement
Related to this article
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5